Interim Analysis of Treatment Outcomes of Young Children with 5q Spinal Muscular Atrophy on Gene Replacement Therapy with Onasemnogene Abeparvovec. Clinical Observations

Background. Onasemnogene abeparvovec is the first gene replacement therapy medication based on the adeno-associated viral vector (AAV9). One injection to a patient with 5q spinal muscular atrophy (SMA) leads to replacement of the missing or defective SMN1 gene with its functional copy. It leads to n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Anna A. Kokorina (Autor), Sergei S. Nikitin (Autor)
Formato: Livro
Publicado em: "Paediatrician" Publishers LLC, 2023-01-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Connect to this object online.

3rd Floor Main Library

Detalhes do Exemplar 3rd Floor Main Library
Número de Chamada: A1234.567
Cópia 1 Disponível